New Cholesterol Guidelines set updated risk tool and LDL targets

Major U.S. heart organizations released revised cholesterol and lipid guidelines that introduce the PREVENT risk calculator, set specific LDL targets by risk level, and recommend at least one Lp(a) test for adults.

The American College of Cardiology, the American Heart Association and other leading medical groups issued a comprehensive update to cholesterol and lipid management. The revision affects how cardiovascular risk is estimated, when treatment is begun, and the LDL targets used in clinical decision-making. The guidelines aim to narrow the gap between clinical knowledge and patient experience by providing clearer benchmarks and tools for assessment and treatment. Key points: - A new risk tool called PREVENT replaces an older calculator that reportedly overestimated 10-year risk by up to 40% to 50%; PREVENT estimates 10-year and 30-year risk and categorizes 10-year risk as low (<3%), borderline (3%–<5%), intermediate (5%–<10%), and high (≥10%). - The guidelines set LDL targets by risk: below 100 mg/dL for borderline/intermediate risk, below 70 mg/dL for high risk, and below 55 mg/dL for very high-risk patients with established cardiovascular disease. - Lp(a) measurement is recommended at least once for all adults, and apolipoprotein B (apoB) testing is recommended for people with diabetes, elevated triglycerides, or metabolic conditions; coronary artery calcium scans may help when risk remains uncertain. - Statins remain the foundation of therapy; for patients not reaching LDL targets on statins alone, the guidelines outline adding non-statin options such as ezetimibe, bempedoic acid, and PCSK9 inhibitors. - The update incorporates multiple "risk enhancers" (for example, family history of heart disease; chronic inflammatory conditions; obesity or chronic kidney disease; higher-risk ancestry such as South Asian or Filipino descent; and reproductive risk markers like early menopause or preeclampsia). - The guidelines include special considerations for people with chronic kidney disease, HIV, type 1 and type 2 diabetes, and those undergoing cancer treatment; most lipid-lowering therapies are advised to be deferred during conception, pregnancy and lactation, and cholesterol screening is recommended to begin in childhood between ages 9 and 11. Summary: The revised guidance changes risk assessment and treatment thresholds by introducing PREVENT, specifying LDL targets, and recommending expanded testing such as Lp(a) and apoB in selected groups. It emphasizes earlier intervention and clearer treatment pathways, while keeping statins as the primary therapy and outlining non-statin options for additional LDL reduction. How quickly the PREVENT tool and these recommendations will be adopted in routine clinical practice is undetermined at this time.